Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease.
Ann Rheum Dis
; 81(1): e11, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-31818808
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Erdheim-Chester Disease
Limits:
Humans
Language:
En
Journal:
Ann Rheum Dis
Year:
2022
Document type:
Article